The positive opinion from CHMP is a crucial regulatory milestone that often precedes market approval. This news is likely to be viewed favorably by investors as it opens up a new market opportunity for Biogen and its treatment for Friedreich's Ataxia, which could lead to increased revenue and profitability in the future. The impact on the stock price should be positive in the short term as the market reacts to this development.